Pulmonary Drug Delivery of Antimicrobials and Anticancer Drugs Using Solid Dispersions

Al-Obaidi, Hisham; Granger, Amy; Hibbard, Thomas; Opesanwo, Sefinat

doi:10.3390/pharmaceutics13071056

Cited by 20 publications

(10 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solid dispersions refer to a formulation technique that involves dispersing a drug in a solid matrix. In this technique, the drug is mixed with an inert carrier molecule, which helps to reduce the loss of the drug within the inhalation device and minimize the deposition of the drug in the oropharyngeal area [ 112 ].…”

Section: Strategies For Drug Targeting Of Nsclcmentioning

confidence: 99%

Inhaled Medicines for Targeting Non-Small Cell Lung Cancer

Al Khatib,

El-Tanani,

Al-Obaidi

2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Throughout the years, considerable progress has been made in methods for delivering drugs directly to the lungs, which offers enhanced precision in targeting specific lung regions. Currently, for treatment of lung cancer, the prevalent routes for drug administration are oral and parenteral. These methods, while effective, often come with side effects including hair loss, nausea, vomiting, susceptibility to infections, and bleeding. Direct drug delivery to the lungs presents a range of advantages. Notably, it can significantly reduce or even eliminate these side effects and provide more accurate targeting of malignancies. This approach is especially beneficial for treating conditions like lung cancer and various respiratory diseases. However, the journey towards perfecting inhaled drug delivery systems has not been without its challenges, primarily due to the complex structure and functions of the respiratory tract. This comprehensive review will investigate delivery strategies that target lung cancer, specifically focusing on non-small-cell lung cancer (NSCLC)—a predominant variant of lung cancer. Within the scope of this review, active and passive targeting techniques are covered which highlight the roles of advanced tools like nanoparticles and lipid carriers. Furthermore, this review will shed light on the potential synergies of combining inhalation therapy with other treatment approaches, such as chemotherapy and immunotherapy. The goal is to determine how these combinations might amplify therapeutic results, optimizing patient outcomes and overall well-being.

show abstract

Section: Strategies For Drug Targeting Of Nsclcmentioning

confidence: 99%

Inhaled Medicines for Targeting Non-Small Cell Lung Cancer

Al Khatib,

El-Tanani,

Al-Obaidi

2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the spray-freeze-drying particles are partially composed of amorphous solids with a large specific surface area, and this state is hygroscopic which can lead to changes in physicochemical properties by humidity when the particles are stored over the long-term or under high humidity conditions such as in the lungs (Tanaka et al., 2020 ). Cocrystal technique has been used to solve such problems (Duggirala et al., 2016 ; Al-Obaidi et al., 2021 ).…”

Section: Production Of Nanocrystals Based Pulmonary Inhalation Systemmentioning

confidence: 99%

Nanocrystals based pulmonary inhalation delivery system: advance and challenge

et al. 2022

View full text Add to dashboard Cite

Pulmonary inhalation administration is an ideal approach to locally treat lung disease and to achieve systemic administration for other diseases. However, the complex nature of the structural characteristics of the lungs often results in the difficulty in the development of lung inhalation preparations. Nanocrystals technology provides a potential formulation strategy for the pulmonary delivery of poorly soluble drugs, owing to the decreased particle size of drug, which is a potential approach to overcome the physiological barrier existing in the lungs and significantly increased bioavailability of drugs. The pulmonary inhalation administration has attracted considerable attentions in recent years. This review discusses the barriers for pulmonary drug delivery and the recent advance of the nanocrystals in pulmonary inhalation delivery. The presence of nanocrystals opens up new prospects for the development of novel pulmonary delivery system. The particle size control, physical instability, potential cytotoxicity, and clearance mechanism of inhaled nanocrystals based formulations are the major considerations in formulation development.

show abstract

“…Pulmonary drug delivery (PDD) is primarily used to treat acute respiratory tract infections as well as chronic respiratory disorders (CRDs); the most common are asthma, chronic obstructive pulmonary disease (COPD), tuberculosis (TB), and lung cancer [ 1 ]. PDD is also used to treat systemic diseases such as diabetes by delivering insulin into the alveolar region for fast absorption into the general circulation.…”

Section: Introductionmentioning

confidence: 99%

Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery

et al. 2023

View full text Add to dashboard Cite

The rapid and non-invasive pulmonary drug delivery (PDD) has attracted great attention compared to the other routes. However, nanoparticle platforms, like liposomes (LPs) and extracellular vesicles (EVs), require extensive reformulation to suit the requirements of PDD. LPs are artificial vesicles composed of lipid bilayers capable of encapsulating hydrophilic and hydrophobic substances, whereas EVs are natural vesicles secreted by cells. Additionally, novel LPs-EVs hybrid vesicles may confer the best of both. The preparation methods of EVs are distinguished from LPs since they rely mainly on extraction and purification, whereas the LPs are synthesized from their basic ingredients. Similarly, drug loading methods into/onto EVs are distinguished whereby they are cell- or non-cell-based, whereas LPs are loaded via passive or active approaches. This review discusses the progress in LPs and EVs as well as hybrid vesicles with a special focus on PDD. It also provides a perspective comparison between LPs and EVs from various aspects (composition, preparation/extraction, drug loading, and large-scale manufacturing) as well as the future prospects for inhaled therapeutics. In addition, it discusses the challenges that may be encountered in scaling up the production and presents our view regarding the clinical translation of the laboratory findings into commercial products.

show abstract

Pulmonary Drug Delivery of Antimicrobials and Anticancer Drugs Using Solid Dispersions

Cited by 20 publications

References 169 publications

Inhaled Medicines for Targeting Non-Small Cell Lung Cancer

Inhaled Medicines for Targeting Non-Small Cell Lung Cancer

Nanocrystals based pulmonary inhalation delivery system: advance and challenge

Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery

Contact Info

Product

Resources

About